¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Schizoaffective disorder, mixed type"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • sexual disorder
    ¼º(Àû)Àå¾Ö
  • shared paranoid disorder
    °øÀ¯ÆíÁýÀå¾Ö
  • single-gene disorder
    ´ÜÀÏÀ¯ÀüÀÚÁúȯ
  • sleep disorder
    ¼ö¸éÀå¾Ö
  • sleep-wake schedule disorder
    ¼ö¸é°¢¼ºÀÏÁ¤Àå¾Ö
  • sleep-wake transition disorder
    ¼ö¸é°¢¼ºÀÌÇàÀå¾Ö
  • temperature-dependent skin disorder
    ¿ÂµµÀÇÁ¸ÇǺκ´
  • unipolar disorder
    ´Ü±Ø¼ºÀå¾Ö, Ȭ±ØÀå¾Ö
  • vascular disorder
    Ç÷°üÀå¾Ö
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • reticuloendothelial disorder
    ¼¼¸Á³»ÇǰèÁúȯ
  • right-left discrimination disorder
    Á¿챸º°Àå¾Ö
  • rumination disorder
    µÇ»õ±èº´, ¹ÝÃߺ´, ¹ÝÃßÀå¾Ö
  • schizophreniform disorder
    Á¤½ÅºÐ¿­ÇüÀå¾Ö, Á¤½ÅºÐ¿­Çüº´
  • seasonal affective disorder
    °èÀýÁ¤µ¿Àå¾Ö, °èÀýÁ¤µ¿º´
  • seizure disorder
    ¹ßÀÛÁúȯ, ¹ßÀÛº´
  • self-control disorder
    ÀÚ±âÁ¶ÀýÀå¾Ö
  • self-defeating personality disorder
    ÀÚ±â¸ð¸êÀΰÝÀå¾Ö, ÀÚ±âÆÐ¹èÀΰÝÀå¾Ö, ÀÚ±âÇø¿ÀÀΰÝÀå¾Ö
  • separation anxiety disorder
    ºÐ¸®ºÒ¾ÈÀå¾Ö, ºÐ¸®ºÒ¾Èº´
  • sex limited disorder
    ÇѼºÀå¾Ö
  • sex-linked disorder
    ¹Ý¼ºÁúȯ, ¼ºµû¸§Áúȯ
  • sexual disorder
    ¼ºÀå¾Ö
  • sexual arousal disorder
    ¼ºÈïºÐÀå¾Ö
  • sexual aversion disorder
    ¼ºÇø¿ÀÀå¾Ö, ¼ºÇø¿Àº´
  • sexual desire disorder
    ¼º¿åÀå¾Ö
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • langhans-type giant cell
    ¶û±×Çѽº°Å´ë¼¼Æ÷, Langerhans °Å´ë¼¼Æ÷(¡­ËÝÓÞá¬øà)
  • lepromatous type
    ³ªÁ¾Çü(ÑÛðþúþ)
  • lepromatous type
    ³ªÁ¾Çü(ÑÛðþúþ).
  • leptosomatic type
    ¸¶¸¥Çü(¡­úþ).
  • limb girdle type
    Áö´ëÇü.
  • linear array type
    ¼±Çü ¹è¿­½Ä (àÊû¡ ÛÕÖªãÒ)
  • linear type constitution
    ¼±Ã¼Çü.
  • lymphatic type
    ¸²ÇÁÇü(¡­úþ).
  • mating type
    ±³¹èÇü
  • men type
    MEN Çü(¡­ û¡)
  • meningeal type
    ¼ö¸·Çü(âÐØ¯úþ).
  • metaphyseal dysostosis dominant type
    °ñ °£´Ü¼º À̰ñÁõ ¿ì¼ºÇü(ÍéÊÏÓ®àõì¶ÍéñøéÐàõúþ).
  • metaplastic bone (type)
    È­»ý°ñ(Çü)(ûùßæÍéû¡).
  • mobile type diagnostic X ray apparatus
    À̵¿Çü Áø´Ü X¼± ÀåÄ¡
  • monocytic type
    ´ÜÇÙ±¸Çü(¡­û¡).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 15
AD accident dispensary; acetate dialysis; active disease; acute dermatomyositis; addict, addiction; ade...
ADCC acute disorder of cerebral circulation; antibody-dependent cell-mediated cytotoxicity
ADD acceptable daily dose; adduction; adenosine deaminase; attentional deficit disorder; average daily d...
ADDH attention deficit disorder with hyperactivity
ADD/HA attention deficit disorder/hyperactivity
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 15
DD Dysthymic Disorder
ED Eating Disorder
EDE Eating Disorder Examination
EDI-2 Eating Disorder Inventory 2
EDNOS Eating Disorder Not Otherwise Specified
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • psychosomatic disorder
    ½É½Å¼º Àå¾Ö, Á¤½Å ½Åü Áúȯ
  • reticuloendothelial disorder
    ¼¼¸Á ³»Çǰè Áúȯ
  • rheumatologic disorder
    ·ù¸¶Æ¼¼º Àå¾Ö, ·ù¸¶Æ¼½º Àå¾Ö
  • schizoid disorder
    ºÐ¿­º´ ºÎÁ¶
  • schizophreniform disorder
    Á¤½Å ºÐ¿­Çü Àå¾Ö
    Áõ»óÀ̳ª ÁõÈÄ´Â Á¤½Å ºÐ¿­ÁõÀ» °¡Áö°í ÀÖÀ¸³ª ±× ±â°£ÀÌ 6°³¿ù¿¡ ¹ÌÄ¡Áö ¸øÇÏ´Â Á¤½Å Àå¾Ö. Àü¿¡´Â ±Þ¼º Á¤½Å ºÐ¿­ÁõÀ̶ó°í ºÒ·¶´Ù.
  • secondary disorder
    ÀÌÂ÷ Àå¾Ö
  • skin disorder
    ÇǺΠÁúȯ
  • sleep terror disorder
    ¾ß°æ Àå¾Ö
    ÀáµéÀÚ °ð Àá¿¡¼­ ±ú¾î³ª °­ÇÑ ºÒ¾È°ú ÀÚÀ²½Å°æ °èÅëÀÇ Áõ»óµéÀÌ ³ªÅ¸³ª ¾Æ¹«¸® ÁøÁ¤½ÃŰ·Á ÇØµµ Àß µèÁö ¾Ê´Â »óŰ¡ µÇÇ®ÀÌÇÏ¿© ÀϾ´Â °Í.
  • somatic disorder
    ½Åü Àå¾Ö
  • somatization disorder
    ½Åüȭ Àå¾Ö
    Áø´Ü¸íÀ¸·Î, ÀüÇüÀûÀÎ È÷½ºÅ׸® ¶Ç´Â ºê¸®ÄÉ ÁõÈıºÀÌ ¾Æ´Ñ ´Ù¹ßÀû ½Åü Áõ»ó È£¼Ò°¡ Ư¡ÀÎ Á¤½Å Àå¾Ö, º´¼ÒÀÇ ³»¿ëÀº Àü¹ÝÀûÀ¸·Î ÀÚÁÖ ¿©±âÀú±â Àß ¾ÆÇÁ´Ù´Â °Í°ú °¡½Å°æÇÐÀûÀΠƯ¼öÇÑ Àüȯ Áõ»ó, ¼ÒÈ­±â°è Áõ»ó, ¿©¼º »ý½Ä±â°è Áõ»ó, Á¤½Å¼º Áõ»ó, ½ÉÆó°è Áõ»ó ¹× ÅëÁõ µîÀÌ´Ù. º´¼Ò´Â °¡²û ±ØÀûÀÌ°í ¸ðÈ£ÇÏ¸ç °úÀåµÈ ÇüÅ·ΠǥÇöµÈ´Ù. ¸¹Àº ÀÇ»çµéÀÌ ÀÌ È¯ÀÚÀÇ ÀÇÇÐÀû Ä¡·á¿¡ °³ÀԵǰí, ¼ö¾øÀÌ ¸¹Àº Áø´Ü °úÁ¤°ú ÇÊ¿ä ¾ø´Â ³»°úÀû Ä¡·á ¶Ç´Â ¼ö¼ú±îÁö ÇÏ°Ô µÈ´Ù. ´ëºÎºÐÀÇ È¯ÀÚµéÀº ºÒ¾È, ¿ì¿ï ¶Ç´Â ±¤¹üÀ§ÇÑ ´ëÀÎ °ü°èÀÇ ¾î·Á¿òÀÌ ÀÖ°í ´ëºÎºÐÀÌ È÷½ºÅ׸®¼º ÀÎ°Ý Æ¯¼ºÀ» °®°í ÀÖ´Ù.
  • somatoform disorder
    ½Åü Àå¾Ö, ½ÅüÇü Àå¾Ö, ½Åüȭ Àå¾Ö
    ±âÁúÀû ¼Ò°ßÀÌ ¾ø´Â ½Åü ÁúȯÀ» ³ªÅ¸³»´Â Áõ»óÀÌ ÀÖ´Â Á¤½ÅÀû »óÅ·μ­ ÀÓ»óÀûÀ¸·Î ÀûÀÀ¼º ±â´É¿¡ ½ÉÇÑ Àå¾ÖÀÇ ¿øÀÎÀÌ µÈ´Ù. DSM-VI´Â ÀÌ·¯ÇÑ Àå¾Ö¿¡ 5°¡Áö°¡ ÀÖ´Ù´Â °ÍÀ» ¾Ë·ÁÁØ´Ù. Áï ½Åüȭ Àå¾Ö
  • somatoform pain disorder
    ½ÅüÇü ÅëÁõ Àå¾Ö
    ÁÖµÈ È£¼Ò°¡ ½ÉÇÑ ¸¸¼º ÅëÁõÀ̰í Àüȯ Àå¾ÖÀÇ Áø´Ü ±âÁØ¿¡ ¸Â´Â °ÍÀÌ Æ¯Â¡ÀÎ Á¤½Å Àå¾Ö. ƯÈ÷, ÅëÁõÀÌ ½Å°æ ÇØºÎ³ª ÀÌ¹Ì ¾Ë·ÁÁø º´»ý¸®ÇÐÀû ±âÀü¿¡ ÀÏÄ¡µÇÁö ¾Ê°í ±âÁúÀû º´¸®ÀÇ º¯È­°¡ ÀÖ´Ù ÇÏ´õ¶óµµ ÅëÁõÀÌ ¿¹»óº¸´Ù ÈξÀ ¸¹°Å³ª ¶Ç´Â Áõ»óµéÀÌ ½É¸®Àû ¿øÀÎÀ» ¸í½ÃÇÏ´Â ÁõÈĸ¦ °®°í ÀÖ´Ù.
  • speech disorder
    ¾ð¾î Àå¾Ö
    ¸»À» ¹Ù¸£°Ô ¹ßÀ½ÇÏÁö ¸øÇϰųª Á¤È®ÇÏ°Ô ÀÌÇØÇÏÁö ¸øÇÏ´Â »óÅÂ. Àΰ£Àº ¸»
  • stereotypy disorder
    »óµ¿ Àå¾Ö, »óµ¿º´
  • systemic disorder
    Àü½Å Àå¾Ö
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
haemadsorption virus type 2 parainfluenza virus type 1
C type lectin <cell biology> One of two classes of lectin produced by animal cells, the other being the S type.
The C type lectins require disulphide linked cysteines and Ca ions in order to bind to a specific carbohydrate (c.f. S type lectins). The carbohydrate recognition domain of C type lectins consists of about 130 amino acids which contains 18 invariant residues in a highly conserved pattern.
These invariant residues include cysteines which probably form disulphide bonds. So far, all identified C type lectins are extracellular proteins and include both Integral membrane proteins, such as the asialoglycoprotein receptor and soluble proteins.
(06 Aug 1998)
C type virus <molecular biology, virology> Originally C type particles identified in mouse tumour tissue and later shown to be oncogenic RNA viruses Oncovirinae) that bud from the plasma membrane of the host cell starting as a characteristic electron dense crescent.
Include feline leukaemia virus, murine leukaemia and sarcoma viruses.
(18 Nov 1997)
haemophilus influenzae type b The majority of type b isolates are from biotype I. The organism can cause life-threatening meningitis, primarily in children 6-12 months of age. Children with underlying disease or immunodeficiency are also at high risk for infection. A vaccine is available and recommended for children under 5 years of age.
(12 Dec 1998)
haemophilus influenzae type b immunization See HIB immunization,
(12 Dec 1998)
Haemophilus influenzae type B vaccine A conjugate of oligosaccharides of the capsular antigen of H. Influenzae type B and diphtheria CRM protein.
(05 Mar 2000)
pre-excitation, mahaim-type A form of pre-excitation characterised by a normal pr interval and a long qrs interval with a delta wave.
(12 Dec 1998)
Hermansky-Pudlak syndrome type VI An autosomal recessive deficiency of pigment in skin, hair, and eyes; in the tyrosinase negative type, there is an absence of tyrosinase; in the tyrosinase positive type, there is normal tyrosinase which cannot enter pigment cells; it is transmitted by an autosomal recessive inheritance. The compound heterozygote is normal so the two forms are not allelic.
There are several types: type IA is characterised by absence of tyrosinase with life-long complete absence of melanin, marked photophobia, and nystagmus. Type IB, yellow albinism with low or absent tyrosinase; improves with age.
Type II, with normal tyrosinase activity is the most common; hair darkens and nevi and freckles develop.
Type III is characterised by absent tyrosinase but pigmentation of the iris in the first decade.
Type IV in Africans with normal tyrosinase.
Type V with red hair.
Type VI, Hermansky-Padlak syndrome, with haemorrhage due to platelet deficiency and low to absent tyrosinase.
Synonym: Hermansky-Pudlak syndrome type VI.
(05 Mar 2000)
herpes simplex type 1 A virus that causes cold sores and fever blisters.
(12 Dec 1998)
herpes simplex type 2 Different from herpes simplex type 1, herpes simplex 2 causes genital herpes.
(12 Dec 1998)
herpes simplex virus type 1 UL13 protein kinase <enzyme> Phosphorylates icp22 and involved in the accumulation of alpha and gamma mrnas and proteins in the infected cells; aa sequence has been determined
Registry number: EC 2.7.1.-
Synonym: ul13 protein kinase, hsv-1, hsv-1 ul13 protein, hsv-1 ul13 pk, u(l)13 protein kinase, protein kinase ul13
(26 Jun 1999)
Schilling type of monocytic leukaemia See: monocytic leukaemia.
(05 Mar 2000)
protoporphyrinogen type III The immediate precursor of protoporphyrin III in haem biosynthesis; elevated in cases of variegate porphyria.
(05 Mar 2000)
protoporphyrinogen type III oxidase A mitochondrial enzyme that uses O2 to convert protoporphyrinogen type III to protoporphyrin type III in haem biosynthesis; a deficiency of this enzyme is associated with variegate porphyria.
(05 Mar 2000)
protoporphyrin type III 2,7,12,18-Tetramethyl-3,8-divinylporphin-13,17dipropionic acid;the principal protoporphyrin found in nature (one of 15 possible isomers), characterised by the presence of 4 methyl groups, 2 vinyl groups, and 2 propionic acid side chains; a porphyrin derivative that, with iron, forms the haem of haemoglobin and the prosthetic groups of myoglobin, catalase, cytochromes, etc.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 15
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 15
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 15
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 15
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 15
ÅëÇÕ°Ë»ö ¿Ï·á